Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies
- 22 January 2010
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 45 (4) , 421-427
Abstract
Earlier work has demonstrated that serum autoantibodies from coeliac patients targeted against transglutaminase 2 (TG2) inhibit in vitro angiogenesis. The aim of this study was to establish whether coeliac patient-derived monoclonal TG2-targeted antibodies produced by recombination technology exert similar anti-angiogenic effects to serum-derived coeliac autoantibodies. In addition, we studied whether the monoclonal patient autoantibodies modulate endothelial cell TG2 activity and whether such modulation is related to the anti-angiogenic effects. The influence of coeliac patient-derived monoclonal TG2-targeted antibodies on endothelial cell tubule formation was studied using a three-dimensional angiogenic cell culture model. Endothelial cell TG2 enzymatic activity was determined by means of a live-cell enzyme-linked immunosorbent assay. Coeliac patient-derived monoclonal TG2-targeted antibodies produced by recombination technology inhibited endothelial tubule formation and enhanced the crosslinking activity of TG2. When this enzymatic activity was inhibited using site-directed irreversible TG2 inhibitors in the presence of autoantibodies, in vitro angiogenesis reverted to the control level. Since we found a significant negative correlation between endothelial cell angiogenesis and TG2 activity, we suggest that the anti-angiogenic effects of coeliac patient-derived TG2-targeted autoantibodies are exerted by enhanced enzymatic activity of TG2.Keywords
This publication has 26 references indexed in Scilit:
- Synthesis of potent water-soluble tissue transglutaminase inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Homocysteine-induced toxicity increases TG2 expression in Neuro2a cellsAmino Acids, 2008
- Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesisClinical and Experimental Immunology, 2008
- Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal modelsBMC Biotechnology, 2007
- Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody depositsGut, 2006
- Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: A prospective and randomized clinical studyScandinavian Journal of Gastroenterology, 2005
- Cell Type-specific Activation of Intracellular Transglutaminase 2 by Oxidative Stress or Ultraviolet IrradiationJournal of Biological Chemistry, 2004
- Tissue Transglutaminase Mediates Activation of RhoA and MAP Kinase Pathways during Retinoic Acid-induced Neuronal Differentiation of SH-SY5Y CellsJournal of Biological Chemistry, 2003
- Phenotype-specific “tissue” transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: Correlation with cell death by apoptosisInternational Journal of Cancer, 1992
- In vivo and in vitro induction of ‘tissue’ transglutaminase in rat hepatocytes by retinoic acidBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992